RT Journal Article
SR Electronic
T1 Evaluation of the Panbio™ rapid antigen test for SARS-CoV-2 in primary health care centers and test sites
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.13.20231316
DO 10.1101/2020.11.13.20231316
A1 Bulilete, Oana
A1 Lorente, Patricia
A1 Leiva, Alfonso
A1 Carandell, Eugenia
A1 Oliver, Antonio
A1 Rojo, Estrella
A1 Pericas, Pau
A1 Llobera, Joan
A1 on behalf of COVID-19 Primary Care Research Group
YR 2020
UL http://medrxiv.org/content/early/2020/11/16/2020.11.13.20231316.abstract
AB Background Rapid antigen tests (Ag-RDT) are emerging as new diagnostic tools for COVID-19 and real-world evaluations are needed to establish their performance characteristics.Main objective To evaluate the accuracy of the Panbio™ Ag-RDT at primary health care (PHC) centers and test sites in symptomatic patients and close contacts, using the Reverse-Transcription Polymerase Chain Reaction (RT-PCR) test as the gold standard.Methods This was a prospective diagnostic study conducted in four PHC centers and two test sites in Mallorca, Spain. Consecutive patients older than 18 years, attending the sites for RT-PCR testing either for suggestive symptoms of infection or a close contact, were included. Two nasopharyngeal samples were collected, one for RT-PCR and the other was processed on-site using the Panbio™ rapid antigen test kit for SARS-CoV-2. The sensitivity and specificity were calculated using RT-PCR as the reference, and the predictive values using the pretest probability results for each analyzed group.Results A total of 1369 participants were included; mean age 42.5 ± 14.9 years and 54.3% women. The overall prevalence was 10.2%. Most participants (70.6%) presented within 5 days of the onset of symptoms or close contact, and more than 70% had high viral loads. The overall sensitivity was of 71.4% (95% CI: 63.1%, 78.7%), the specificity of 99.8% (95% CI: 99.4%, 99.9%), the positive predictive value of 98.0% (95% CI: 93.0%, 99.7%) and a negative predictive value of 96.8% (95% CI: 95.7%, 97.7%). The sensitivity was higher in symptomatic patients, in those arriving within 5 days since symptom onset and in those with high viral load.Conclusion Ag-RDT had relatively good performance characteristics in suspected symptomatic patients within five days since the onset of symptoms. However, our results concludes that a negative Ag-RDT in these settings must be considered as presumptive.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Balearic Public Health Service (Servei de Salut de les Illes Balears) had endorsed the study, bought Panbio COVID-19 Antigen Rapid Test Device and provided the human and logistic resources for its accomplishment. No external funding was received. Servei de Salut de les Illes Balears had no role in the design, study management, data analysis, result interpretation or in the writing of the paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted following the Declaration of Helsinki and was approved by the Balearic Research Ethics Committee (IB 4350/20 PI on 30/09/2020) and by the Mallorca Primary Care Research Commission. All participants had signed the informed consent before inclusion.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe anonymized database set is available at http://doi.org/10.5281/zenodo.4264502. http://doi.org/10.5281/zenodo.4264502